Skip to main content
KISSEI PHARMACEUTICAL CO.,LTD. logo

KISSEI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4547 ISIN · JP3240600001 T Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2024-12-27 Major Shareholding Noti…
Country JP Japan
Listing T 4547

About KISSEI PHARMACEUTICAL CO.,LTD.

https://www.kissei.co.jp/e_contents/

Kissei Pharmaceutical Co., Ltd. is a research-driven company engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The company concentrates its research and development investments in key therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its broader product portfolio also addresses conditions in metabolic and endocrinological, obstetrics and gynecological, and ophthalmic fields. Committed to creating innovative medicines, Kissei aims to contribute to global health by addressing unmet medical needs. The company also operates in the health foods sector.

Recent filings

Filing Released Lang Actions
大量保有報告書
Major Shareholding Notification Classification · 100% confidence The document explicitly states its title multiple times: "株券等の大量保有の状況の開示に関する内閣府令 第一号様式 大量保有報告書" (Cabinet Office Ordinance on Disclosure of Large Volume Shareholdings Form No. 1 Large Volume Report). This document details the ownership status of shares by Kissei Pharmaceutical Co., Ltd. in Alpico Holdings Co., Ltd., including the number of shares held (4,000,000 shares, 5.41% ownership) and details about any agreements or funding sources. This type of filing in Japan, reporting ownership exceeding 5% of a listed company's shares, is a specific regulatory disclosure. Among the provided codes, there is no direct equivalent for a Japanese 'Large Volume Report' (大量保有報告書). However, this filing concerns a change in significant share ownership, which aligns conceptually with the definition of 'Major Shareholding Notification' (MRQ). It is a mandatory disclosure regarding ownership thresholds, not a general earnings release (ER), annual report (10-K), or management discussion (MDA). Therefore, MRQ is the most appropriate classification.
2024-12-27 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document header explicitly states the filing type as "自己株券買付状況報告書" (Report on the Status of Treasury Stock Acquisition). The legal basis cited is Article 24-6, Paragraph 1 of the Financial Instruments and Exchange Act. The content details the acquisition and subsequent disposition (including cancellation/retiring) of treasury stock during the reporting period (November 1 to November 30, 2024). This specific reporting requirement for share repurchases aligns directly with the definition of a Transaction in Own Shares report, which corresponds to the code POS (Transaction in Own Shares).
2024-12-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (Kakuninsho) filed under the Financial Instruments and Exchange Act in Japan. It serves as an officer certification confirming the accuracy of a previously filed semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 80
2024-11-13 Japanese
半期報告書－第80期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Kissei Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis (MDA), and corporate information for the interim period (April 1, 2024, to September 30, 2024). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements, it is classified as an Interim/Quarterly Report. H1 2025
2024-11-13 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is filed with the Kanto Local Finance Bureau. The content explicitly details the resolutions passed at the '第79期定時株主総会' (79th Annual General Meeting) held on June 25, 2024. It lists the agenda items (dividend, articles of incorporation change, election of directors/auditors) and the voting results (votes for, against, abstentions, and approval status). This structure perfectly matches the definition of reporting the results of a shareholder meeting, which falls under the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). Although it relates to an AGM, the primary function here is reporting the *results* of the vote, not providing the presentation materials (AGM-R). The document length is short (2790 chars), suggesting it is an official filing announcing the outcome rather than the full meeting transcript or presentation.
2024-06-28 Japanese
内部統制報告書－第79期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document header explicitly states the filing type as "内部統制報告書" (Internal Control Report) and cites the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法). The content discusses the framework, scope, criteria, and conclusion regarding the assessment of internal controls over financial reporting (財務報告に係る内部統制). This directly corresponds to the requirements for an Audit Report/Information filing, specifically concerning internal control assessments, which falls under the 'AR' category in the provided definitions, as it is a standalone report on internal controls rather than the full Annual Report (10-K) or a mere announcement of a report.
2024-06-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.